Amanta Healthcare Ltd Upgraded to Hold on Technical and Financial Improvements

Quality Assessment: Mixed Fundamental Signals

Amanta Healthcare’s quality rating remains tempered by its weak long-term fundamental strength. The company has experienced a negative compound annual growth rate (CAGR) of -2.00% in net sales over the past five years, indicating challenges in sustaining revenue growth. Additionally, its debt servicing ability is constrained, with a high Debt to EBITDA ratio of 3.11 times, signalling elevated leverage risks.

However, recent quarterly performance has shown encouraging signs. For the nine months ending December 2025, the company reported a profit after tax (PAT) of ₹10.75 crores, representing a robust growth of 73.88% year-on-year. Operating profit to interest coverage ratio reached a healthy 3.04 times, the highest recorded, suggesting improved operational efficiency and debt servicing capacity in the short term. Net sales for the quarter also hit a peak of ₹74.49 crores.

Return on capital employed (ROCE) stands at 14%, which is a respectable figure for a micro-cap pharmaceutical firm, indicating effective utilisation of capital resources. Despite these positives, the overall quality grade remains cautious due to the company’s historical sales decline and leverage concerns.

Valuation: Attractive Metrics Amid Micro-Cap Status

Amanta Healthcare’s valuation has become more appealing, supported by an enterprise value to capital employed ratio of 1.9, which suggests the stock is reasonably priced relative to the capital it employs. The company’s market capitalisation remains in the micro-cap category, which often entails higher volatility but also potential for outsized returns if growth materialises.

Its current share price stands at ₹120.46, up 6.59% on the day, with a 52-week range between ₹93.25 and ₹154.85. The stock has outperformed the Sensex significantly over recent periods, delivering a 10.98% return in the past week and an impressive 25.41% gain over the last month, compared to Sensex returns of 0.71% and 4.76% respectively. Year-to-date, Amanta Healthcare has returned 10.82%, while the Sensex declined by 8.34%, highlighting strong relative momentum.

Financial Trend: Positive Quarterly Momentum

The financial trend for Amanta Healthcare has improved markedly in the recent quarter ending December 2025. The company’s PAT growth of 73.88% over nine months is a standout metric, reflecting operational improvements and better cost management. Net sales reaching ₹74.49 crores mark the highest quarterly sales figure recorded, underscoring a potential turnaround in revenue generation.

Operating profit to interest coverage ratio at 3.04 times indicates the company’s enhanced ability to meet interest obligations, a critical factor given its previously high leverage. Despite these gains, the company’s long-term sales trajectory remains a concern, with a negative 5-year CAGR in net sales. Profit growth of 189% over the past year, however, suggests that recent operational efficiencies may be translating into improved bottom-line results.

Technicals: Upgrade to Mildly Bullish Outlook

The most significant driver behind the upgrade to a Hold rating is the shift in technical indicators. The technical trend has moved from sideways to mildly bullish, signalling growing investor confidence and positive price momentum. Key technical signals include:

• Bollinger Bands (Weekly): Bullish, indicating price volatility is supporting upward movement.
• Dow Theory (Weekly): Mildly bullish, suggesting a nascent uptrend in the stock price.
• On-Balance Volume (OBV): Mildly bullish on both weekly and monthly charts, reflecting accumulation by investors.

Other indicators such as MACD and KST remain neutral or show no clear signal, while the monthly Dow Theory remains bearish, indicating some caution for longer-term investors. The stock’s daily price action has been positive, with the current price at ₹120.46, up from the previous close of ₹113.01 and a day’s high of ₹125.00.

This technical improvement has been pivotal in shifting the MarketsMOJO Mojo Grade from Sell to Hold, with the overall Mojo Score now at 50.0. The stock remains a Hold recommendation, reflecting balanced risk and reward prospects.

Comparative Performance and Market Context

Amanta Healthcare’s recent returns have outpaced the broader market benchmark, the Sensex, by a wide margin. Over the last week, the stock gained 10.98% compared to the Sensex’s 0.71%. Over one month, the stock surged 25.41%, while the Sensex rose 4.76%. Year-to-date, the stock has returned 10.82%, contrasting with the Sensex’s decline of 8.34%. These figures highlight the stock’s strong relative momentum within the Pharmaceuticals & Biotechnology sector.

Despite this, the company’s longer-term returns are not available (NA) for one, three, five, and ten-year periods, reflecting either limited trading history or data gaps. The Sensex, by comparison, has delivered 1.79% over one year, 29.26% over three years, 60.05% over five years, and 204.80% over ten years, underscoring the broader market’s sustained growth over time.

Shareholding and Sector Positioning

Promoters remain the majority shareholders of Amanta Healthcare, maintaining control over strategic decisions. The company operates within the Pharmaceuticals & Biotechnology industry, a sector known for its growth potential but also for regulatory and competitive challenges. As a micro-cap entity, Amanta Healthcare carries higher risk but also the possibility of significant upside if it can sustain its recent operational improvements and capitalise on favourable technical trends.

Conclusion: A Cautious Hold with Upside Potential

The upgrade of Amanta Healthcare Ltd’s investment rating from Sell to Hold reflects a nuanced assessment of its current position. Improved technical indicators, notably the shift to a mildly bullish trend, have been instrumental in this change. Positive quarterly financial results, including strong PAT growth and record net sales, support a more optimistic outlook.

However, the company’s weak long-term sales growth and high leverage remain concerns that temper enthusiasm. The valuation appears attractive relative to capital employed, but investors should remain mindful of the micro-cap risks and sector volatility.

Overall, Amanta Healthcare is positioned as a Hold with potential upside, suitable for investors willing to monitor its evolving fundamentals and technical momentum closely.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →